Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 15/20 | 0.75 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283932 | 1.00 | STING1 (0.75) | STING1PDE3BPDE3APDE4APDE4B | |
| SCHEMBL13341127 | 1.00 | STING1 (0.75) | STING1PDE3BPDE3APDE4APDE4B | |
| SCHEMBL25063900 | 0.89 | STING1 (0.85) | STING1LMNA | |
| SCHEMBL26351022 | 0.89 | STING1 (0.85) | STING1LMNA | |
| SCHEMBL24649405 | 0.89 | STING1 (0.85) | STING1LMNA | |
| SCHEMBL19954144 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL24467522 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21470181 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21498373 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL17974376 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-04-30 | — | — | US | disclosed |
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2026-01-20 | — | — | US | disclosed |
| EP-4676590-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | Zoetis Services LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250367191-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH A CNS-PENETRANT SGC STIMULATOR ZAGOCIGUAT | TISENTO THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250341515-A1 | METABOLOMIC BIOMARKERS FOR ACUTE KIDNEY INJURY, ASSAYS, COMPOSITIONS AND METHODS OF USE THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325518-A1 | USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | NOVARTIS AG (CH) | 2025-10-23 | — | — | US | disclosed |
| US-20250255821-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250205298-A1 | HERBAL COMPOSITION FOR ENHANCING SEXUAL WELLNESS AND MUSCLE STRENGTH IN HUMAN BEINGS | NATURAL AND ESSENTIAL OILS PRIVATE LIMITED (IN) | 2025-06-26 | — | — | US | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| CN-114947087-A | Novel composite milk jujube jam and preparation method thereof | 天津科技大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220227812-A1 | Treatments for Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS INC (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220202725-A1 | Modified or Targeted Release Formulations of Linaclotide | IRONWOOD PHARMACEUTICALS INC (US) | 2022-06-30 | — | — | US | disclosed |
| EP-2997998-B1 | THERAPY DEVICE FOR EDEMA AND NEUROPATHY | COLOR SEVEN CO LTD (KR) | 2022-06-29 | — | — | EP | disclosed |
| CN-114616242-A | CNP variants and conjugates thereof | 生物马林药物股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| CN-114423447-A | Hydrophobic peptide salts for extended release compositions | 生物马林药物股份有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220119452-A1 | Treatments for Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220031802-A1 | Low-Dose Stable Formulations of Linaclotide | IRONWOOD PHARMACEUTICALS INC (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202725-A1 | Modified or Targeted Release Formulations of Linaclotide | LPXN, MLNR, LHCGR | STING1 3474/4885PDE3B 59/4885PDE3A 37/4885 |
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | SCN8A, SCN9A, VIP | STING1 1743/4885PDE3B 2323/4885PDE3A 2208/4885 |
| US-20250367191-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH A CNS-PENETRANT SGC STIMULATOR ZAGOCIGUAT | PDE3B, OTC, GUCY1A1 | STING1 293/4885PDE3B 1/4885PDE3A 12/4885 |
| US-20250325518-A1 | USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | MME, ACE, REN | STING1 3737/4885PDE3B 2470/4885PDE3A 1898/4885 |
| US-20250255821-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | GMPS, PRKG1, GUCY1A2 | STING1 773/4885PDE3B 7/4885PDE3A 5/4885 |
| US-20220227812-A1 | Treatments for Gastrointestinal Disorders | GRPR, GIPR, GCGR | STING1 862/4885PDE3B 41/4885PDE3A 50/4885 |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VIP, MLEC, SEC16A | STING1 1453/4885PDE3B 3833/4885PDE3A 3573/4885 |
| US-20220031802-A1 | Low-Dose Stable Formulations of Linaclotide | LPXN, PDE8A, PDE8B | STING1 3028/4885PDE3B 52/4885PDE3A 24/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | STING1 3316/4885PDE3B 456/4885PDE3A 609/4885 |
| US-20220119452-A1 | Treatments for Gastrointestinal Disorders | GRPR, GIPR, GCGR | STING1 862/4885PDE3B 41/4885PDE3A 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.